USD 1.73
(2.37%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 394 Thousand CAD | -73.27% |
2022 | 1.47 Million CAD | -91.91% |
2021 | 18.21 Million USD | 2112.88% |
2020 | 823 Thousand CAD | -7.63% |
2019 | 891 Thousand CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | 0.0% |
2005 | - CAD | 0.0% |
2004 | - CAD | 0.0% |
2003 | - CAD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 401 Thousand CAD | 0.0% |
2024 Q1 | 401 Thousand CAD | 1.78% |
2023 Q1 | 1.38 Million USD | -6.17% |
2023 Q2 | 1.2 Million CAD | -12.58% |
2023 Q4 | 394 Thousand CAD | -64.05% |
2023 FY | 394 Thousand CAD | -73.27% |
2023 Q3 | 1.09 Million CAD | -9.35% |
2022 Q2 | 16.45 Million CAD | -6.79% |
2022 Q3 | 1.98 Million CAD | -87.96% |
2022 Q1 | 17.65 Million CAD | -3.06% |
2022 Q4 | 1.47 Million CAD | -25.59% |
2022 FY | 1.47 Million CAD | -91.91% |
2021 Q2 | 12.99 Million CAD | 8.66% |
2021 Q1 | 11.95 Million CAD | 1352.98% |
2021 Q3 | 17.29 Million CAD | 33.12% |
2021 Q4 | 18.21 Million USD | 5.3% |
2021 FY | 18.21 Million USD | 2112.88% |
2020 Q2 | 867 Thousand CAD | -7.77% |
2020 Q4 | 823 Thousand CAD | -2.72% |
2020 Q3 | 846 Thousand CAD | -2.42% |
2020 Q1 | 940 Thousand CAD | 5.5% |
2020 FY | 823 Thousand CAD | -7.63% |
2019 Q1 | 850 Thousand CAD | 0.0% |
2019 FY | 891 Thousand CAD | 0.0% |
2019 Q2 | 873 Thousand CAD | 2.71% |
2019 Q3 | 872 Thousand CAD | -0.11% |
2019 Q4 | 891 Thousand CAD | 2.18% |
2018 Q1 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2006 Q4 | - CAD | 0.0% |
2006 FY | - CAD | 0.0% |
2006 Q2 | - CAD | 0.0% |
2006 Q1 | - CAD | 0.0% |
2006 Q3 | - CAD | 0.0% |
2005 Q4 | - CAD | 0.0% |
2005 FY | - CAD | 0.0% |
2005 Q1 | - CAD | 0.0% |
2005 Q3 | - CAD | 0.0% |
2005 Q2 | - CAD | 0.0% |
2004 Q3 | - CAD | 0.0% |
2004 Q4 | - CAD | 0.0% |
2004 Q1 | - CAD | 0.0% |
2004 FY | - CAD | 0.0% |
2004 Q2 | - CAD | 0.0% |
2003 Q3 | - CAD | 0.0% |
2003 Q2 | - CAD | 0.0% |
2003 FY | - CAD | 0.0% |
2003 Q4 | - CAD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.873% |
Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.567% |
Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.92% |
Cosmos Health Inc. | 3.03 Million USD | 87.02% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1652.357% |
Esperion Therapeutics, Inc. | 501.54 Million USD | 99.921% |
Cronos Group Inc. | 1.55 Million USD | 74.727% |
Incannex Healthcare Limited | 210 Thousand USD | -87.619% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | 98.848% |
Lifecore Biomedical, Inc. | 120.51 Million USD | 99.673% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | 26.906% |
Sunshine Biopharma, Inc. | 539.03 Thousand USD | 26.906% |
SCYNEXIS, Inc. | 12.15 Million USD | 96.76% |
Safety Shot Inc | 304.9 Thousand USD | -29.22% |
Theratechnologies Inc. | 51.26 Million USD | 99.231% |
Alpha Teknova, Inc. | 13.25 Million USD | 97.027% |
Universe Pharmaceuticals INC | - USD | -Infinity% |
Pacira BioSciences, Inc. | 513.79 Million USD | 99.923% |
Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -352.874% |
Dynavax Technologies Corporation | 252.41 Million USD | 99.844% |
Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.921% |
Radius Health, Inc. | 339.66 Million USD | 99.884% |
China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -236.381% |
Alvotech | 1.02 Billion USD | 99.962% |
Intra-Cellular Therapies, Inc. | 13.32 Million USD | 97.043% |
SIGA Technologies, Inc. | 335.99 Thousand USD | -17.265% |
Shineco, Inc. | 10.01 Million USD | 96.067% |
Silver Spike Investment Corp. | - USD | -Infinity% |
Journey Medical Corporation | 14.62 Million USD | 97.305% |
Petros Pharmaceuticals, Inc. | 6.85 Million USD | 94.254% |
Embecta Corp. | 1.62 Billion USD | 99.976% |
Harrow Health, Inc. | 183.17 Million USD | 99.785% |
Procaps Group, S.A. | 28.41 Million USD | 98.613% |
Biofrontera Inc. | 804 Thousand USD | 50.995% |
DURECT Corporation | 2.7 Million USD | 85.418% |
PainReform Ltd. | 30 Thousand USD | -1213.333% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 98.813% |
OptiNose, Inc. | 611 Thousand USD | 35.516% |
RedHill Biopharma Ltd. | 455 Thousand USD | 13.407% |
Organogenesis Holdings Inc. | 60.74 Million USD | 99.351% |
Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 96.918% |
ProPhase Labs, Inc. | 10.25 Million USD | 96.159% |
Phibro Animal Health Corporation | 458.28 Million USD | 99.914% |
Procaps Group S.A. | 28.41 Million USD | 98.613% |
TherapeuticsMD, Inc. | 6.53 Million USD | 93.968% |
Viatris Inc. | 16.18 Billion USD | 99.998% |
Rockwell Medical, Inc. | 8.29 Million USD | 95.249% |
Aytu BioPharma, Inc. | 10.87 Million USD | 96.378% |
Tilray Brands, Inc. | 287.93 Million USD | 99.863% |
PetIQ, Inc. | 437.82 Million USD | 99.91% |
Talphera, Inc. | - USD | -Infinity% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.847% |
Alimera Sciences, Inc. | 64.48 Million USD | 99.389% |
Assertio Holdings, Inc. | 38.51 Million USD | 98.977% |
Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -191.66% |
Avadel Pharmaceuticals plc | 32.75 Million USD | 98.797% |
Hempacco Co., Inc. | 5.93 Million USD | 93.357% |
Alvotech | 1.02 Billion USD | 99.962% |
Lantheus Holdings, Inc. | 616.12 Million USD | 99.936% |
Kamada Ltd. | 7.43 Million USD | 94.703% |
Currenc Group, Inc. | 2.5 Million USD | 84.284% |
Indivior PLC | 235.66 Million USD | 99.833% |
Evoke Pharma, Inc. | 5 Million USD | 92.12% |
Flora Growth Corp. | 942 Thousand USD | 58.174% |
Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1652.357% |
Evolus, Inc. | 120.35 Million USD | 99.673% |
HUTCHMED (China) Limited | 48.18 Million USD | 99.182% |
Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.933% |
Akanda Corp. | 2.49 Million USD | 84.222% |